Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 22, Issue 6, Pages 751-763Publisher
INFORMA HEALTHCARE
DOI: 10.1517/13543784.2013.802768
Keywords
beta-cell failure; ER stress; inflammation; insulin resistance; type 2 diabetes; tyrosine kinase inhibitors
Categories
Funding
- [FAPESP: 2012/10338-6]
- [CNPq-INCT: 573856/2008-7]
Ask authors/readers for more resources
Introduction: Some inhibitors of tyrosine kinase, as imatinib, erlotinib and sunitinib have antihyperglycemic effects but the mechanisms are not totally clear. Areas covered: It is well established that insulin resistance and beta-cell failure are hallmarks of type 2 diabetes mellitus (DM2). The present review will discuss the molecular mechanisms that account for insulin resistance and beta-cell failure in DM2, and also the effect of tyrosine kinase inhibitors in these processes. Expert opinion: A better understanding of how these drugs improve the two most important mechanisms of DM2 associated with suggestions of clinical studies will lead to improve the treatment of this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available